In addition, accumulated evidence indicates that miR-148 also plays an important role in some non-tumor diseases, such as IgA nephropathy, type 2 diabetes (T2D) and liver injury, etc. In IgA nephropathy patients, miR-148b induced o-glycosylation abnormalities by targeting C1GALT1 [31]. Here, C1GALT1 is linked to IgA glomerulonephritis.